# US 2020/0390708 A1 · Multilayer beads for pharmaceutical use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390708 A1
- Document ID: US20200390708A1
- Status: Published application
- Kind: A1
- Application number: 16/338,948
- Filed: 2017-10-05
- Published: 2020-12-17
- Earliest claimed: 2016-10-06
- Assignees: Sucampo AG
- Applicants: Sucampo AG
- Inventors: Deepak Tiwari; Yasuhiro Harada; Ryu Hirata
- Web page: https://patentgrep.com/patent/US20200390708A1

## CPC

- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/558: having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/10: Laxatives
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Multilayer beads for pharmaceutical use having a drug-in-polymer layer are disclosed. The disclosed multilayer beads for pharmaceutical use have (a) a core particle; (b) an optional barrier layer coated on the surface of the core particle; (c) a drug-in-polymer layer coated on the surface of the core or the barrier layer, (d) an optional sealant layer coated on the surface of the drug-in-polymer layer; and (e) optionally one or more outer layers external to the drug-in-polymer layer or the sealant layer. The drug-in-polymer layer consists essentially of (i) a drug selected from the group consisting of a 15-keto prostaglandin drug, a 13,14-dihydro prostaglandin drug, and a 13,14-dihydro-15-keto prostaglandin drug; and (ii) a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or a mixture thereof. The drug-in-polymer layer may be solid dispersion of the drug in the polymer. Pharmaceutical compositions comprising a plurality of multilayer beads and a pharmaceutically acceptable excipient and methods of treating a gastrointestinal disorder are also disclosed.

## Claims

### Claim at position 1

1-70. (canceled)

### Claim 71

A multilayer bead comprising:
(a) a core particle;
(b) an optional barrier layer coated on the surface of the core particle;
(c) a drug-in-polymer layer coated on the surface of the core particle or, when present, the barrier layer, wherein the drug-in-polymer layer comprises:
(i) a drug selected from the group consisting of a 15-keto prostaglandin drug, a 13,14-dihydro prostaglandin drug, and a 13,14-dihydro-15-keto prostaglandin drug; and
(ii) a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof;
(d) an optional sealant layer coated on the surface of the drug-in-polymer layer; and
(e) optionally one or more outer layers external to the drug-in-polymer layer or, when present, the sealant layer.

### Claim 72 (depends on 71)

The multilayer bead of claim 71, wherein the core particle is selected from the group consisting of microcrystalline cellulose particles, silica particles, and sugar particles.

### Claim 73 (depends on 71)

The multilayer bead of claim 71, wherein the drug is selected from the group consisting of:
(−)-7-[(2R,4aR,5R,7aR)-2-(I,I-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid (lubiprostone);
(−)-7-{(2R,4aR,5R,7aR)-2-[(3S)-I,I-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid (cobiprostone);
(+)-isopropyl (Z)-7-[(IR,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoate (isopropyl unoprostone);
(Z)-7-[(IR,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid;
(−)-7-[(IR,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid; and
(E)-7-[(IR,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid.

### Claim 74 (depends on 71)

The multilayer bead of claim 71, wherein the drug is present in an amount from about 0.01 μg to about 0.2 μg.

### Claim 75 (depends on 71)

The multilayer bead of claim 71, wherein the drug and the polymer are present in a relative amount from about 1 part drug per about 0.2 part polymer to about 1 part drug per about 10,000 parts polymer.

### Claim 76 (depends on 71)

The multilayer bead of claim 71, wherein the barrier layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof.

### Claim 77 (depends on 71)

The multilayer bead of claim 71, wherein the sealant layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof.

### Claim 78 (depends on 71)

The multilayer bead of claim 71, wherein at least one outer layer is present and comprises a polymer that insoluble at a pH ranging from 5 to 8 and is soluble at pH ranging from 1 to 4, or a polymer that is insoluble at a pH ranging from 6 to 8 and is soluble at pH ranging from 1 to 5.

### Claim 79 (depends on 71)

The multilayer bead of claim 71, wherein at least one outer layer is present and comprises a methacrylate-based polymer.

### Claim 80 (depends on 71)

The multilayer bead of claim 71, wherein the barrier layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof, and the sealant layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof.

### Claim 81 (depends on 80)

The multilayer bead of claim 80, wherein:
(a) the core particle comprises microcrystalline cellulose;
(b) the barrier layer comprises a vinylpyrrolidone-vinyl acetate copolymer;
(c) the drug-in-polymer layer comprises a therapeutically effective amount of lubiprostone or a pharmaceutically acceptable salt or isomer thereof and a vinylpyrrolidone-vinyl acetate copolymer; and
(d) the sealant layer comprises a vinylpyrrolidone-vinyl acetate copolymer.

### Claim 82 (depends on 71)

The multilayer bead of claim 71, wherein:
(a) the core particle comprises microcrystalline cellulose;
(b) the barrier layer is present and comprises a vinylpyrrolidone-vinyl acetate copolymer;
(c) the drug-in-polymer layer comprises a therapeutically effective amount of lubiprostone or a pharmaceutically acceptable salt or isomer thereof and a vinylpyrrolidone-vinyl acetate copolymer;
(d) the sealant layer is present and comprises a vinylpyrrolidone-vinyl acetate copolymer; and
(e) one outer layer is present and comprises a copolymer comprising butyl methacrylate.

### Claim 83 (depends on 82)

The multilayer bead of claim 82, wherein the barrier layer, drug-in-polymer layer, sealant layer, outer layer, or any combination thereof comprises one or more pharmaceutically acceptable excipients.

### Claim 84 (depends on 83)

The multilayer bead of claim 83, wherein the one or more pharmaceutically acceptable excipients is talc, polyethylene glycol, or a combination thereof.

### Claim 85 (depends on 82)

The multilayer bead of claim 82, wherein lubiprostone is present in an amount from about 0.01 μg to about 0.2 μg.

### Claim 86 (depends on 85)

The multilayer bead of claim 85, wherein the amount of lubiprostone is from about 0.04 μg to about 0.08 μg.

### Claim 87 (depends on 82)

The multilayer bead of claim 82, wherein lubiprostone and the vinylpyrrolidone-vinyl acetate copolymer are present in a relative amount from about 1 part lubiprostone per about 0.2 part vinylpyrrolidone-vinyl acetate copolymer to about 1 part lubiprostone per about 10,000 parts vinylpyrrolidone-vinyl acetate copolymer.

### Claim 88 (depends on 87)

The multilayer bead of claim 87, wherein the relative amount of lubiprostone and the vinylpyrrolidone-vinyl acetate copolymer is from about 1 part lubiprostone per about 200 parts vinylpyrrolidone-vinyl acetate copolymer to about 1 part lubiprostone per about 1,000 parts vinylpyrrolidone-vinyl acetate copolymer.

### Claim 89 (depends on 71)

A pharmaceutical composition comprising a plurality of multilayer beads according to claim 71 and at least one pharmaceutically acceptable excipient.

### Claim 90 (depends on 89)

The pharmaceutical composition of claim 89, wherein the plurality of multilayer beads is contained in a capsule, a sachet, or a pouch.

### Claim 91 (depends on 90)

The pharmaceutical composition of claim 90, wherein the capsule is a sprinkle capsule.

### Claim 92 (depends on 89)

The pharmaceutical composition of claim 89, wherein the plurality of multilayer beads provides from about 1 μg to about 75 μg of the drug.

### Claim 93 (depends on 92)

The pharmaceutical composition of claim 92, wherein the drug is lubiprostone.

### Claim 94 (depends on 89)

A method for treating a gastrointestinal disorder, the method comprising orally administering to a patient in need thereof a therapeutically effective amount of the multilayer beads in the pharmaceutical composition of claim 89.

### Claim 95 (depends on 94)

The method of claim 94, further comprising sprinkling the multilayer beads in pharmaceutical composition into water or onto a soft food substance prior to orally administering to the patient.

### Claim 96 (depends on 94)

The method of claim 94, wherein the gastrointestinal disorder is selected from the group consisting of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation.

### Claim 97 (depends on 94)

The method of claim 94, wherein the patient is a pediatric patient or a geriatric patient.
